Phase I Study of Weekly MLN9708 in Relapsed/Refractory Multiple Myeloma


Phase I Study of Weekly MLN9708 in Relapsed/Refractory Multiple Myeloma
Slides from a presentation at ASCO 2013 and transcribed comments from a recent interview with Antonio Palumbo, MD (8/20/13)
Kumar SK et al. Weekly MLN9708, an investigational oral proteasome inhibitor, in relapsed/refractory multiple myeloma: Results from a Phase I study after full enrollment. Proc ASCO 2013;Abstract 8514.

Dr Palumbo is Chief of the Myeloma Unit in the University of Torino’s Division of Hematology in Torino, Italy.